A retrospective, non-interventional, observational, multi-center, chart review study to be conducted in participants who underwent placement of the XEN 45 Gel Stent as a standalone procedure or in combination with phacoemulsification from 1 January 2014 to 1 October 2015.
Study Type
OBSERVATIONAL
Enrollment
174
Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015.
Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015.
Clinical Trials Registry Team
Irvine, California, United States
Change From Baseline in Mean Intraocular Pressure (IOP) to 36 Months After Implantation
IOP is a measurement of the fluid pressure inside the eye. A negative change from Baseline indicates an improvement.
Time frame: Baseline (Day decision was made to implant XEN 45 Gel Stent) to 36 months after implantation
Change From Baseline in the Number of Topical IOP-lowering Medications 36 Months After Implantation
IOP-lowering medications included Beta blocking agents, Carbonic anhydrase inhibitors, Parasympathomimetics, Prostaglandin analogues, and Sympathomimetics in glaucoma therapy.
Time frame: Baseline (Day decision was made to implant XEN 45 Gel Stent) to 36 months after implantation
Change From Baseline in Mean IOP to 48 Months After Implantation
IOP is a measurement of the fluid pressure inside the eye. A negative change from Baseline indicates an improvement.
Time frame: Baseline (Day decision was made to implant XEN 45 Gel Stent) to 48 months after implantation
Change From Baseline in the Number of Topical IOP-lowering Medications 48 Months After Implantation
IOP-lowering medications included Beta blocking agents, Carbonic anhydrase inhibitors, Parasympathomimetics, Prostaglandin analogues, and Sympathomimetics in glaucoma therapy.
Time frame: Baseline (Day decision was made to implant XEN 45 Gel Stent) to 48 months after implantation
Percentage of Eyes Achieving Qualified Success at Month 36
Qualified success of implantation of the XEN 45 Gel Stent is defined as ≥20% reduction in IOP from medicated baseline with no SSI for glaucoma and no clinical hypotony while staying on the same number or fewer topical IOP-lowering medications than at Baseline.
Time frame: Baseline (Day decision was made to implant XEN 45 Gel Stent), Month 36
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Percentage of Eyes Achieving Qualified Success at Month 48
Qualified success of implantation of the XEN 45 Gel Stent is defined as ≥20% reduction in IOP from medicated baseline with no SSI for glaucoma and no clinical hypotony while staying on the same number or fewer topical IOP-lowering medications than at Baseline.
Time frame: Baseline (Day decision was made to implant XEN 45 Gel Stent), Month 48
Percentage of Eyes Achieving Complete Success at Month 36
Complete success of implantation of the XEN 45 Gel Stent is defined as ≥20% reduction in IOP from Baseline with no SSI for glaucoma and no clinical hypotony while taking no topical IOP-lowering medications.
Time frame: Baseline (Day decision was made to implant XEN 45 Gel Stent), Month 36
Percentage of Eyes Achieving Complete Success at Month 48
Complete success of implantation of the XEN 45 Gel Stent is defined as ≥20% reduction in IOP from Baseline with no SSI for glaucoma and no clinical hypotony while taking no topical IOP-lowering medications.
Time frame: Baseline (Day decision was made to implant XEN 45 Gel Stent), Month 48
Percentage of Eyes With Adverse Events of Special Interest (AESIs)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with use of a drug whether or not it is considered related to drug. AESI include: Glaucoma, defined as damage to optic nerve with progressive vision loss, Intraocular hypertension, defined as IOP without meeting criteria for glaucoma, Hypotony, defined as low IOP ≤5 mmHg, Cataract or lens opacities, Ocular bleeding or hemorrhage, Retinal detachment, tear or hole, Vitreous detachment, Infection vs. Non-infection related Ocular inflammation, Significant vitreous loss, Mechanical failure of device and implant misplacement, Implant dislocation. Data of AESIs are presented based on eyes for this outcome measure.
Time frame: Baseline (Day decision was made to implant XEN 45 Gel Stent) to approximately 51 Months